EVGN Evogene Ltd. IFRS Annual reports only
Agricultural Chemicals · Nasdaq · SEC CIK 1574565 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.85M | $5.58M |
| Cost of revenue | $4.09M | $2.38M |
| Gross profit | -$241,000 | $3.20M |
| R&D expense | $7.99M | $12.51M |
| SG&A expense | $4.29M | $6.99M |
| Operating income | -$14.03M | -$18.80M |
| Interest expense | $1.93M | $3.36M |
| Pretax income | -$13.50M | -$14.81M |
| Income tax | $1,000 | $9,000 |
| Net income | -$8.48M | -$16.48M |
| EBITDA | -$12.89M | -$17.42M |
| EPS (basic) | 1.08 | -2.90 |
| EPS (diluted) | 1.08 | -2.90 |
| Weighted avg. shares (diluted) | 7.87M | 5.70M |
| Balance sheet | ||
| Cash & equivalents | $12.96M | $15.30M |
| Short-term investments | — | $10,000 |
| Receivables | $317,000 | $1.09M |
| Inventory | $210,000 | $1.82M |
| Current assets | $15.63M | $21.59M |
| PP&E, netmay include right-of-use assets (IFRS) | $812,000 | $1.80M |
| Intangibles | $0 | $12.20M |
| Total assets | $20.05M | $39.86M |
| Current liabilities | $3.44M | $18.70M |
| Total liabilities | $8.07M | $25.03M |
| Shareholders' equity | -$82,000 | -$1.45M |
| Shares outstanding | 8.72M | 6.51M |
| Cash flow statement | ||
| Operating cash flow | -$13.50M | -$19.70M |
| Capital expenditure | $135,000 | $626,000 |
| Free cash flow | -$13.64M | -$20.33M |
| Investing cash flow | $17.74M | $9.62M |
| Financing cash flow | -$6.60M | $4.66M |
| Depreciation & amortization | $1.14M | $1.38M |
| Stock-based compensation | $654,000 | $1.24M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.